Interviews

Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities.

Generics Bulletin editor Dave Wallace talks to John Murphy III, president and CEO of the US Association for Accessible Medicines, about the association’s latest annual savings report and key topics affecting the US off-patent market.

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

Charl van Zyl tells Scrip that pipeline is the priority as the company discontinues commercial operations in 27 markets.

“We’ve invested billions of dollars and have achieved over $12bn in revenues since we launched our first biosimilars,” Amgen’s biosimilars head, Marc Doble, tells Generics Bulletin as part of an exclusive interview, which explores how the firm’s biosimilars benefit from its roots in biologics.

In the wake of a major transaction that saw private-equity firm EQT take control of Alvo group B2B business Adalvo, CEO Anil Okay talks to Generics Bulletin about what the deal means for Adalvo and how it is planning to expand in future.

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

Co-founders name their company for their grandmothers – Opal, a Texan rancher, and Joy, a New Zealand artist – to symbolize strength and creativity. Their brand’s premium, ethical ingredients and formulations were developed by a female women’s health doctor.

In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.